Polyinosinic-polycytidylic acidPolyinosinic-polycytidylic acid
MedChemExpress (MCE)
HY-107202
24939-03-5
Poly(I:C)
99.4%
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) induces a dose- and time-dependent increase in paracellular permeability of immortalized airway epithelial cells[4]. Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) does not have cytotoxicity to 16HBE14o- cells[4]. Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) induces disruption of epithelial apical junctional complexes (AJCs) and tight junctions (TJs) in 16HBE14o- cells[4].
Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) induces a sustained inflammatory reaction in the substantia nigra (SN) and in the dorsolateral striatum. [2]. Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) decreases lung tumor growth in mice[3]. Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) exerts therapeutic effects against cerebral I/R injury through the downregulation of TLR4/MyD88 signaling via TLR3 in MCAO model mice[5].
Bcl-2 Bax IL-17A IL-13 HSP70
| | | |
| | | | | |
[1]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.
[2]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.
[3]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.
[4]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.
[5]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.
[6]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001
413(6857):732-738. [Content Brief]
[7]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002
293(5):1364-1369. [Content Brief]